Alkem Laboratories
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
July 1 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM LABS - COMMISSIONER OF INCOME TAX DELETES DISALLOWANCES INVOLVING TAX AMOUNT OF 6.61 BILLION RUPEES
Source text: ID:nNSE3vVtKN
Further company coverage: ALKE.NS
(([email protected];))
July 1 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM LABS - COMMISSIONER OF INCOME TAX DELETES DISALLOWANCES INVOLVING TAX AMOUNT OF 6.61 BILLION RUPEES
Source text: ID:nNSE3vVtKN
Further company coverage: ALKE.NS
(([email protected];))
May 28 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
DIVIDEND OF 10 RUPEES PER SHARE
Q4 CONSOL NET PROFIT 2.36 BILLION RUPEES; IBES PROFIT EST. 4.7 BILLION RUPEES
Q4 CONSOL REVENUE FROM OPERATIONS 36.03 BILLION RUPEES; IBES EST. 35.3 BILLION RUPEES
ONE-TIME CHARGE OF 1.35 BILLION RUPEES IN Q4
Source text: ID:nnAZN4SZ33B
Further company coverage: ALKE.NS
(([email protected];;))
May 28 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
DIVIDEND OF 10 RUPEES PER SHARE
Q4 CONSOL NET PROFIT 2.36 BILLION RUPEES; IBES PROFIT EST. 4.7 BILLION RUPEES
Q4 CONSOL REVENUE FROM OPERATIONS 36.03 BILLION RUPEES; IBES EST. 35.3 BILLION RUPEES
ONE-TIME CHARGE OF 1.35 BILLION RUPEES IN Q4
Source text: ID:nnAZN4SZ33B
Further company coverage: ALKE.NS
(([email protected];;))
** Shares of India's Alkem Laboratories ALKE.NS up 3.89% at 5,614.5 rupees
** The pharmaceutical firm received a favourable Order-in-Appeal from a statutory authority, that dropped a GST demand of 696.6 million rupees ($7.33 million)
** Company sees no material impact on its financials, operation or other activities
** ALKE stock rated "buy" on avg by 17 analysts; median PT:5890 rupees - LSEG-compiled data
** YTD, Alkem stock down 1.88%
($1 = 95.0725 Indian rupees)
(Reporting by Devika Nair in Bengaluru)
(([email protected];))
** Shares of India's Alkem Laboratories ALKE.NS up 3.89% at 5,614.5 rupees
** The pharmaceutical firm received a favourable Order-in-Appeal from a statutory authority, that dropped a GST demand of 696.6 million rupees ($7.33 million)
** Company sees no material impact on its financials, operation or other activities
** ALKE stock rated "buy" on avg by 17 analysts; median PT:5890 rupees - LSEG-compiled data
** YTD, Alkem stock down 1.88%
($1 = 95.0725 Indian rupees)
(Reporting by Devika Nair in Bengaluru)
(([email protected];))
May 5 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM LABS - ORDER-IN-APPEAL DROPS TAX DEMAND OF 696.6 MILLION RUPEES
Source text: ID:nBSE4HspdS
Further company coverage: ALKE.NS
(([email protected];))
May 5 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM LABS - ORDER-IN-APPEAL DROPS TAX DEMAND OF 696.6 MILLION RUPEES
Source text: ID:nBSE4HspdS
Further company coverage: ALKE.NS
(([email protected];))
** Shares of India's Alkem Laboratories ALKE.NS down 4.15% to 5,288 rupees
** Pharmaceutical firm's CEO Vikas Gupta steps down from his position
** ALKE rated "hold" on avg by 19 analysts; median TP 5,890 rupees
** YTD stock up 0.25%
(Reporting by Devika Nair in Bengaluru)
(([email protected];))
** Shares of India's Alkem Laboratories ALKE.NS down 4.15% to 5,288 rupees
** Pharmaceutical firm's CEO Vikas Gupta steps down from his position
** ALKE rated "hold" on avg by 19 analysts; median TP 5,890 rupees
** YTD stock up 0.25%
(Reporting by Devika Nair in Bengaluru)
(([email protected];))
April 2 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM LABS - BOARD APPROVES INCREASE IN INVESTMENT TO UP TO 10.36 BILLION RUPEES FROM 5.33 BILLION RUPEES FOR UJJAIN FACILITY
Source text: ID:nNSE5jQ6DC
Further company coverage: ALKE.NS
(([email protected];))
April 2 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM LABS - BOARD APPROVES INCREASE IN INVESTMENT TO UP TO 10.36 BILLION RUPEES FROM 5.33 BILLION RUPEES FOR UJJAIN FACILITY
Source text: ID:nNSE5jQ6DC
Further company coverage: ALKE.NS
(([email protected];))
March 30 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM LABS - INCORPORATES WHOLLY OWNED SUBSIDIARY IN DUBAI HEALTHCARE CITY, UAE
Source text: ID:nNSE8MRbg1
Further company coverage: ALKE.NS
(([email protected];))
March 30 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM LABS - INCORPORATES WHOLLY OWNED SUBSIDIARY IN DUBAI HEALTHCARE CITY, UAE
Source text: ID:nNSE8MRbg1
Further company coverage: ALKE.NS
(([email protected];))
March 23 (Reuters) - At least half a dozen Indian generic drugmakers launched cheaper versions of Novo Nordisk's NOVOb.CO blockbuster diabetes drug Ozempic and weight‑loss drug Wegovy over the weekend, at globally unmatched prices and slashing treatment costs by about 70%.
The patent for semaglutide, the active ingredient in Novo's drugs, expired in India last week, paving the way for drugmakers to flood the market with dozens of brands.
Analysts expect more than 40 Indian drugmakers to launch over 50 cheaper variants.
Large Indian drugmakers are racing to capture a share of the global obesity market, projected to be worth about $100 billion by the end of the decade. They are eyeing overseas markets, including Canada, Brazil, Latin America, and Turkey, for future launches.
Here is a list of Indian drugmakers that have launched generic semaglutide in recent days:
SUN PHARMACEUTICAL SUN.NS
India's largest drugmaker by revenue launched semaglutide injectable under the brand name Noveltreat for chronic weight management in five dose strengths from 0.25 mg to 2.4 mg and Sematrinity in two dose strengths for type 2 diabetes. Noveltreat is expected to cost around 900 to 2000 rupees ($9.58-$21.30) for weekly treatment, and Sematrinity will cost 750 to 1300 rupees ($7.99-$13.84), the company said.
DR REDDY'S LABORATORIES REDY.NS
The Hyderabad-based drugmaker launched semaglutide under the brand name Obeda for diabetes in 2 mg and 4 mg dose strengths in a disposable pen device format. Each pen of both strengths will deliver a minimum of four weekly doses and cost about 4200 rupees ($44.73) per month, the company said.
ZYDUS LIFESCIENCES ZYDU.NS
The company launched generic injectable semaglutide under three different brand names- Semaglyn, Mashema, and Alterme - for diabetes and obesity treatment in a reusable pen device. The average monthly cost of the treatment will be approximately 2,200 rupees ($23.43), the company said.
TORRENT PHARMACEUTICALS TORP.NS
The company launched an oral and injectable semaglutide drug under the brand names Sembolic and Semalix. The starting price for the injectable drugs would be 3,999 rupees ($42.59) per month, the company said.
GLENMARK PHARMACEUTICALS GLEN.NS
Glenmark launched injectable semaglutide, branded as GLIPIQ, in vial and pen formats for diabetes treatment. The vial is estimated to cost around 1,300 to 1,760 rupees for a month's usage. ($13.84-$18.74).
ALKEM LABORATORIES ALKE.NS
The company said its semaglutide, launched under three brand names - Semasize, Obesema, and Hepaglide - will be available in a pre-filled disposable injection pen and cost starting at 1,800 rupees ($19.17) per month.
ERIS LIFESCIENCES ERIS.NS
The company launched generic semaglutide in a vial format named 'Sundae.' The starting price for the multi-dose vials is 1,290 rupees ($13.74) per month. Eris is also in partnership with Natco Pharma NATP.NS, which has also launched its own generic semaglutide, for commercial manufacturing of the drug.
($1 = 93.9000 Indian rupees)
(Reporting by Rishika Sadam; Editing by Rashmi Aich)
(([email protected];))
March 23 (Reuters) - At least half a dozen Indian generic drugmakers launched cheaper versions of Novo Nordisk's NOVOb.CO blockbuster diabetes drug Ozempic and weight‑loss drug Wegovy over the weekend, at globally unmatched prices and slashing treatment costs by about 70%.
The patent for semaglutide, the active ingredient in Novo's drugs, expired in India last week, paving the way for drugmakers to flood the market with dozens of brands.
Analysts expect more than 40 Indian drugmakers to launch over 50 cheaper variants.
Large Indian drugmakers are racing to capture a share of the global obesity market, projected to be worth about $100 billion by the end of the decade. They are eyeing overseas markets, including Canada, Brazil, Latin America, and Turkey, for future launches.
Here is a list of Indian drugmakers that have launched generic semaglutide in recent days:
SUN PHARMACEUTICAL SUN.NS
India's largest drugmaker by revenue launched semaglutide injectable under the brand name Noveltreat for chronic weight management in five dose strengths from 0.25 mg to 2.4 mg and Sematrinity in two dose strengths for type 2 diabetes. Noveltreat is expected to cost around 900 to 2000 rupees ($9.58-$21.30) for weekly treatment, and Sematrinity will cost 750 to 1300 rupees ($7.99-$13.84), the company said.
DR REDDY'S LABORATORIES REDY.NS
The Hyderabad-based drugmaker launched semaglutide under the brand name Obeda for diabetes in 2 mg and 4 mg dose strengths in a disposable pen device format. Each pen of both strengths will deliver a minimum of four weekly doses and cost about 4200 rupees ($44.73) per month, the company said.
ZYDUS LIFESCIENCES ZYDU.NS
The company launched generic injectable semaglutide under three different brand names- Semaglyn, Mashema, and Alterme - for diabetes and obesity treatment in a reusable pen device. The average monthly cost of the treatment will be approximately 2,200 rupees ($23.43), the company said.
TORRENT PHARMACEUTICALS TORP.NS
The company launched an oral and injectable semaglutide drug under the brand names Sembolic and Semalix. The starting price for the injectable drugs would be 3,999 rupees ($42.59) per month, the company said.
GLENMARK PHARMACEUTICALS GLEN.NS
Glenmark launched injectable semaglutide, branded as GLIPIQ, in vial and pen formats for diabetes treatment. The vial is estimated to cost around 1,300 to 1,760 rupees for a month's usage. ($13.84-$18.74).
ALKEM LABORATORIES ALKE.NS
The company said its semaglutide, launched under three brand names - Semasize, Obesema, and Hepaglide - will be available in a pre-filled disposable injection pen and cost starting at 1,800 rupees ($19.17) per month.
ERIS LIFESCIENCES ERIS.NS
The company launched generic semaglutide in a vial format named 'Sundae.' The starting price for the multi-dose vials is 1,290 rupees ($13.74) per month. Eris is also in partnership with Natco Pharma NATP.NS, which has also launched its own generic semaglutide, for commercial manufacturing of the drug.
($1 = 93.9000 Indian rupees)
(Reporting by Rishika Sadam; Editing by Rashmi Aich)
(([email protected];))
March 21 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM LABS - LAUNCHES SEMAGLUTIDE INJECTION IN INDIA WITH WEEKLY THERAPY STARTING AT 450 RUPEES
ALKEM LABS - SEMAGLUTIDE PRE-FILLED PEN AVAILABLE AT 1,800 RUPEES FOR FOUR DOSES PER MONTH
ALKEM LABS - LAUNCHES SEMAGLUTIDE UNDER BRAND NAMES SEMASIZE, OBESEMA, AND HEPAGLIDE
Source text: ID:nNSE7pZ5Bp
Further company coverage: ALKE.NS
(([email protected];))
March 21 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM LABS - LAUNCHES SEMAGLUTIDE INJECTION IN INDIA WITH WEEKLY THERAPY STARTING AT 450 RUPEES
ALKEM LABS - SEMAGLUTIDE PRE-FILLED PEN AVAILABLE AT 1,800 RUPEES FOR FOUR DOSES PER MONTH
ALKEM LABS - LAUNCHES SEMAGLUTIDE UNDER BRAND NAMES SEMASIZE, OBESEMA, AND HEPAGLIDE
Source text: ID:nNSE7pZ5Bp
Further company coverage: ALKE.NS
(([email protected];))
Novo Nordisk's India patent on semaglutide expires this week
Move to trigger wave of cheaper generics from local drugmakers
Concerns raised about misuse, uneven oversight
By Rishika Sadam
HYDERABAD, March 19 (Reuters) - India's market for diabetes and weight-loss drugs is set for a shake-up as Danish drugmaker Novo Nordisk's NOVOb.CO patent on semaglutide expires this week, triggering a wave of cheaper generics from local drugmakers and worries about uneven oversight in an overcrowded market.
More than 40 Indian firms are expected to launch over 50 brands within weeks, analysts and doctors said, widening access in a price-sensitive market, but also raising concerns about misuse and confusion among prescribers as costs fall sharply.
Sun Pharma SUN.NS, Mankind Pharma MNKI.NS, Dr. Reddy's REDY.NS, Zydus ZYDU.NS, Lupin LUPN.NS and Alkem ALKE.NS are among the companies expected to launch generic versions of semaglutide, the active ingredient in Novo's diabetes drug Ozempic and weight-loss treatment Wegovy.
"With high demand, falling prices and multiple brands, you may see direct pharmacy purchases, distributor-level leakages, or cosmetic or lifestyle use especially in urban markets," said Salil Kallianpur, an independent analyst.
"This could lead to misuse, poor titration and unmanaged side effects and eventually regulatory tightening."
India's drug regulator did not respond to a request for comment. Semaglutide is a prescription drug, but enforcement in India has often been uneven, with doctors and pharmacists playing a key gatekeeping role.
The entry of generics will also challenge Novo and U.S. rival Eli Lilly LLY.N, which launched blockbuster diabetes and obesity drugs in India last year, as they seek to cement their position in the country.
Lilly's Mounjaro became India's top-selling drug by value within months of launch, according to data from Pharmarack, a research firm.
India, the world's most populous nation, has the second-highest number of adults with diabetes after China and could have more than 440 million overweight or obese people by 2050, according to The Lancet, a medical journal, and the International Diabetes Federation.
India's obesity drug market could grow to 80 billion rupees ($856.6 million) by 2030 from about 15 billion rupees today, according to Pharmarack estimates.
EYES ON THE PRICE
Indian generic drugmakers, known globally for producing low-cost medicines, are expected to price their generics at discounts of at least 50% to 60%.
Analysts say monthly prices for the lowest dose could fall from about 11,000 rupees to 3,000 to 5,000 rupees as early generics arrive and eventually to around 1,500 to 2,500 rupees, expanding access beyond a niche urban elite.
"I will consult my doctor to check if I can move to using a generic version, as that appears to be lighter on the pocket," said 32-year-old Vishal, a tech worker from Hyderabad, who is considering a switch from Wegovy.
Many other patients in India's out-of-pocket market have also begun enquiring about cheaper options, some of which are expected to launch as soon as Saturday, the day after Novo's patent expires.
"The price range being quoted is broadly 2,500 to 3,500 rupees, which is quite low," said bariatric surgeon Venugopal Pareek. Six of his patients are waiting for generic versions to switch from Novo or Lilly drugs.
Lower prices are expected to expand the patient pool.
"Onboarding of patients from lower economic strata may happen on branded generics," said Sheetal Sapale, commercial vice president at Pharmarack, noting that company profits would depend on pricing discipline.
Novo and Lilly did not immediately respond to Reuters requests for a comment.
DOCTORS' CHOICE
Even as prices fall, analysts say the winner in the market will depend not just on cost, but also on doctor confidence.
India's pharmaceutical market is heavily driven by physician prescriptions and uptake will depend on doctors' familiarity and confidence in individual brands.
An initial glut of products is likely to overwhelm prescribers, analysts said, with uneven experiences and aggressive marketing.
Many generic drugmakers are opting for brand names that incorporate "sema," which could also add to confusion.
Over time, analysts expect doctors' trust to consolidate around a handful of players offering reliable supply, quality delivery devices and consistent outcomes.
"Weaker players with poor quality and no differentiation will likely exit within two to three years," Kallianpur said.
(Reporting by Rishika Sadam; Editing by Dhanya Skariachan and Thomas Derpinghaus)
(([email protected];))
Novo Nordisk's India patent on semaglutide expires this week
Move to trigger wave of cheaper generics from local drugmakers
Concerns raised about misuse, uneven oversight
By Rishika Sadam
HYDERABAD, March 19 (Reuters) - India's market for diabetes and weight-loss drugs is set for a shake-up as Danish drugmaker Novo Nordisk's NOVOb.CO patent on semaglutide expires this week, triggering a wave of cheaper generics from local drugmakers and worries about uneven oversight in an overcrowded market.
More than 40 Indian firms are expected to launch over 50 brands within weeks, analysts and doctors said, widening access in a price-sensitive market, but also raising concerns about misuse and confusion among prescribers as costs fall sharply.
Sun Pharma SUN.NS, Mankind Pharma MNKI.NS, Dr. Reddy's REDY.NS, Zydus ZYDU.NS, Lupin LUPN.NS and Alkem ALKE.NS are among the companies expected to launch generic versions of semaglutide, the active ingredient in Novo's diabetes drug Ozempic and weight-loss treatment Wegovy.
"With high demand, falling prices and multiple brands, you may see direct pharmacy purchases, distributor-level leakages, or cosmetic or lifestyle use especially in urban markets," said Salil Kallianpur, an independent analyst.
"This could lead to misuse, poor titration and unmanaged side effects and eventually regulatory tightening."
India's drug regulator did not respond to a request for comment. Semaglutide is a prescription drug, but enforcement in India has often been uneven, with doctors and pharmacists playing a key gatekeeping role.
The entry of generics will also challenge Novo and U.S. rival Eli Lilly LLY.N, which launched blockbuster diabetes and obesity drugs in India last year, as they seek to cement their position in the country.
Lilly's Mounjaro became India's top-selling drug by value within months of launch, according to data from Pharmarack, a research firm.
India, the world's most populous nation, has the second-highest number of adults with diabetes after China and could have more than 440 million overweight or obese people by 2050, according to The Lancet, a medical journal, and the International Diabetes Federation.
India's obesity drug market could grow to 80 billion rupees ($856.6 million) by 2030 from about 15 billion rupees today, according to Pharmarack estimates.
EYES ON THE PRICE
Indian generic drugmakers, known globally for producing low-cost medicines, are expected to price their generics at discounts of at least 50% to 60%.
Analysts say monthly prices for the lowest dose could fall from about 11,000 rupees to 3,000 to 5,000 rupees as early generics arrive and eventually to around 1,500 to 2,500 rupees, expanding access beyond a niche urban elite.
"I will consult my doctor to check if I can move to using a generic version, as that appears to be lighter on the pocket," said 32-year-old Vishal, a tech worker from Hyderabad, who is considering a switch from Wegovy.
Many other patients in India's out-of-pocket market have also begun enquiring about cheaper options, some of which are expected to launch as soon as Saturday, the day after Novo's patent expires.
"The price range being quoted is broadly 2,500 to 3,500 rupees, which is quite low," said bariatric surgeon Venugopal Pareek. Six of his patients are waiting for generic versions to switch from Novo or Lilly drugs.
Lower prices are expected to expand the patient pool.
"Onboarding of patients from lower economic strata may happen on branded generics," said Sheetal Sapale, commercial vice president at Pharmarack, noting that company profits would depend on pricing discipline.
Novo and Lilly did not immediately respond to Reuters requests for a comment.
DOCTORS' CHOICE
Even as prices fall, analysts say the winner in the market will depend not just on cost, but also on doctor confidence.
India's pharmaceutical market is heavily driven by physician prescriptions and uptake will depend on doctors' familiarity and confidence in individual brands.
An initial glut of products is likely to overwhelm prescribers, analysts said, with uneven experiences and aggressive marketing.
Many generic drugmakers are opting for brand names that incorporate "sema," which could also add to confusion.
Over time, analysts expect doctors' trust to consolidate around a handful of players offering reliable supply, quality delivery devices and consistent outcomes.
"Weaker players with poor quality and no differentiation will likely exit within two to three years," Kallianpur said.
(Reporting by Rishika Sadam; Editing by Dhanya Skariachan and Thomas Derpinghaus)
(([email protected];))
March 18 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM LABS - RECEIVES 30 ACRE LAND ALLOTMENT IN UJJAIN FOR GREENFIELD FACILITY
ALKEM LABS - APPROVED INVESTMENT OF UPTO 5.33 BILLION RUPEES TO BE MADE IN PHASED MANNER
Source text: ID:nNSE867KBB
Further company coverage: ALKE.NS
(([email protected];))
March 18 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM LABS - RECEIVES 30 ACRE LAND ALLOTMENT IN UJJAIN FOR GREENFIELD FACILITY
ALKEM LABS - APPROVED INVESTMENT OF UPTO 5.33 BILLION RUPEES TO BE MADE IN PHASED MANNER
Source text: ID:nNSE867KBB
Further company coverage: ALKE.NS
(([email protected];))
Axsome Therapeutics has reached a settlement with Alkem Laboratories to resolve patent litigation related to Axsome's product Sunosi. Under the agreement, Alkem will be licensed to sell a generic version of Sunosi in the United States beginning on or after September 1, 2040, if pediatric exclusivity is granted, or on or after March 1, 2040, if not. The settlement is subject to regulatory review, and related litigation with another party remains pending in the U.S. District Court for the District of New Jersey.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9655420-en) on February 17, 2026, and is solely responsible for the information contained therein.
Axsome Therapeutics has reached a settlement with Alkem Laboratories to resolve patent litigation related to Axsome's product Sunosi. Under the agreement, Alkem will be licensed to sell a generic version of Sunosi in the United States beginning on or after September 1, 2040, if pediatric exclusivity is granted, or on or after March 1, 2040, if not. The settlement is subject to regulatory review, and related litigation with another party remains pending in the U.S. District Court for the District of New Jersey.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9655420-en) on February 17, 2026, and is solely responsible for the information contained therein.
Feb 16 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM LABS - USFDA ISSUES FORM 483 WITH 6 PROCEDURAL OBSERVATIONS
ALKEM LABS - USFDA INSPECTION AT MANUFACTURING FACILITY OF ENZENE BIOSCIENCES
Source text: ID:nBSE6BrxyZ
Further company coverage: ALKE.NS
(([email protected];;))
Feb 16 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM LABS - USFDA ISSUES FORM 483 WITH 6 PROCEDURAL OBSERVATIONS
ALKEM LABS - USFDA INSPECTION AT MANUFACTURING FACILITY OF ENZENE BIOSCIENCES
Source text: ID:nBSE6BrxyZ
Further company coverage: ALKE.NS
(([email protected];;))
Feb 13 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM MEDTECH TO BUY 51%-55% OF OCCLUTECH
TOTAL EQUITY VALUE IS EUR 180.70 MILLION
Source text: ID:nBSE4gygN5
Further company coverage: ALKE.NS
(([email protected];))
Feb 13 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM MEDTECH TO BUY 51%-55% OF OCCLUTECH
TOTAL EQUITY VALUE IS EUR 180.70 MILLION
Source text: ID:nBSE4gygN5
Further company coverage: ALKE.NS
(([email protected];))
Rewrites to add new information throughout
By Rishika Sadam and Kashish Tandon
Jan 23 (Reuters) - Indian drugmakers Sun Pharmaceutical Industries SUN.NS, Zydus Lifesciences ZYDU.NS and Alkem Laboratories ALKE.NS have received approval from India's regulator to manufacture and sell generic versions of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic.
Data on the regulator's website show Zydus Lifesciences ZYDU.NS and Alkem Laboratories ALKE.NS received approval last week to manufacture and sell generic semaglutide for weight-loss and diabetes treatment, intensifying competition in the obesity-drug race in the world's most populous nation.
The companies, which are yet to announce the approval, did not immediately respond to Reuters' request for a comment.
Sun Pharma, which is India's largest drugmaker by revenue, on Friday announced that it had been granted approval and would be launching generics under brand names Noveltreat for obesity and Sematrinity for diabetes.
Semaglutide, the active ingredient in Danish drugmaker Novo Nordisk's NOVOb.CO Wegovy and its diabetes drug Ozempic, is set for patent expiry in March 2026.
The upcoming patent expiry for semaglutide opens the door for Indian generic drugmakers to enter the weight-loss market with cheaper versions of both Wegovy and Ozempic at steep discounts.
Last year, U.S. drugmaker Eli Lilly LLY.N launched Mounjaro in India, while Novo introduced Wegovy and Ozempic. Sales of the innovator drugs doubled shortly after launch.
The global weight-loss drug market is projected to reach $150 billion by the end of the decade.
Ozempic, though mainly approved for type 2 diabetes, is also used off-label for weight loss due to its appetite-suppressing effects.
Earlier this week, Dr Reddy's Laboratories REDY.NS said it had obtained approval to sell the generic version of Ozempic.
"The generic players will come in with lower prices and expand the number of people they can reach out to given their aggressive marketing strategy," said Vishal Manchanda, an analyst with Systematix Institutional Equities, adding that there are at least a dozen other generic companies awaiting approvals.
(Reporting by Rishika Sadam in Hyderabad and Kashish Tandon in Bengaluru; Editing by Sherry Jacob-Phillips and Tasim Zahid)
Rewrites to add new information throughout
By Rishika Sadam and Kashish Tandon
Jan 23 (Reuters) - Indian drugmakers Sun Pharmaceutical Industries SUN.NS, Zydus Lifesciences ZYDU.NS and Alkem Laboratories ALKE.NS have received approval from India's regulator to manufacture and sell generic versions of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic.
Data on the regulator's website show Zydus Lifesciences ZYDU.NS and Alkem Laboratories ALKE.NS received approval last week to manufacture and sell generic semaglutide for weight-loss and diabetes treatment, intensifying competition in the obesity-drug race in the world's most populous nation.
The companies, which are yet to announce the approval, did not immediately respond to Reuters' request for a comment.
Sun Pharma, which is India's largest drugmaker by revenue, on Friday announced that it had been granted approval and would be launching generics under brand names Noveltreat for obesity and Sematrinity for diabetes.
Semaglutide, the active ingredient in Danish drugmaker Novo Nordisk's NOVOb.CO Wegovy and its diabetes drug Ozempic, is set for patent expiry in March 2026.
The upcoming patent expiry for semaglutide opens the door for Indian generic drugmakers to enter the weight-loss market with cheaper versions of both Wegovy and Ozempic at steep discounts.
Last year, U.S. drugmaker Eli Lilly LLY.N launched Mounjaro in India, while Novo introduced Wegovy and Ozempic. Sales of the innovator drugs doubled shortly after launch.
The global weight-loss drug market is projected to reach $150 billion by the end of the decade.
Ozempic, though mainly approved for type 2 diabetes, is also used off-label for weight loss due to its appetite-suppressing effects.
Earlier this week, Dr Reddy's Laboratories REDY.NS said it had obtained approval to sell the generic version of Ozempic.
"The generic players will come in with lower prices and expand the number of people they can reach out to given their aggressive marketing strategy," said Vishal Manchanda, an analyst with Systematix Institutional Equities, adding that there are at least a dozen other generic companies awaiting approvals.
(Reporting by Rishika Sadam in Hyderabad and Kashish Tandon in Bengaluru; Editing by Sherry Jacob-Phillips and Tasim Zahid)
Jan 13 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM LABS - GETS TAX DEMAND OF 38.3 MILLION RUPEES; TAX PENALTY OF 3.8 MILLION RUPEES
Source text: ID:nnAZN4RXVG9
Further company coverage: ALKE.NS
(([email protected];))
Jan 13 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM LABS - GETS TAX DEMAND OF 38.3 MILLION RUPEES; TAX PENALTY OF 3.8 MILLION RUPEES
Source text: ID:nnAZN4RXVG9
Further company coverage: ALKE.NS
(([email protected];))
Jan 8 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
LAUNCHES RENOCIA CYCLICAL THERAPY KIT TO SUPPORT HAIR GROWTH
Source text: ID:nNSE6cDgf2
Further company coverage: ALKE.NS
(([email protected];))
Jan 8 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
LAUNCHES RENOCIA CYCLICAL THERAPY KIT TO SUPPORT HAIR GROWTH
Source text: ID:nNSE6cDgf2
Further company coverage: ALKE.NS
(([email protected];))
Jan 1 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
GETS TAX PENALTY OF 10.9 MILLION RUPEES
Source text: ID:nNSE9Lr9b5
Further company coverage: ALKE.NS
(([email protected];))
Jan 1 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
GETS TAX PENALTY OF 10.9 MILLION RUPEES
Source text: ID:nNSE9Lr9b5
Further company coverage: ALKE.NS
(([email protected];))
Nov 13 (Reuters) - Alkem Laboratories ALKE.NS:
SEPT-QUARTER CONSOL NET PROFIT 7.65 BILLION RUPEES
SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 40.01 BILLION RUPEES
Source text: ID:nBSEBpBhz
Further company coverage: ALKE.NS
(([email protected];))
Nov 13 (Reuters) - Alkem Laboratories ALKE.NS:
SEPT-QUARTER CONSOL NET PROFIT 7.65 BILLION RUPEES
SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 40.01 BILLION RUPEES
Source text: ID:nBSEBpBhz
Further company coverage: ALKE.NS
(([email protected];))
Sept 24 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
GETS TAX ORDER DEMAND OF 2.3 MILLION RUPEES
Further company coverage: ALKE.NS
(([email protected];;))
Sept 24 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
GETS TAX ORDER DEMAND OF 2.3 MILLION RUPEES
Further company coverage: ALKE.NS
(([email protected];;))
** Alkem Laboratories ALKE.NS rises 0.5% to 5,451 rupees
** Nomura retains "buy"; raises PT to 6,300 from 5,393 rupees, implying 16.2% upside to last close
** Sees recovery in domestic business, growth potential in Enzene Biosciences, Alkem's biotechnology subsidiary
** Sees growth opportunity in co's obesity drug
** Expects Enzene revenue to rise to 8 bln rupees ($91.5 mln) by FY28 vs year-ago 3.6 bln rupees
** Stock rated "hold" on avg; median PT is 5,430 rupees, per data compiled by LSEG
** YTD, ALKE falls 3.2%
($1 = 87.4300 Indian rupees)
(Reporting by Rudra Singh)
(([email protected];))
** Alkem Laboratories ALKE.NS rises 0.5% to 5,451 rupees
** Nomura retains "buy"; raises PT to 6,300 from 5,393 rupees, implying 16.2% upside to last close
** Sees recovery in domestic business, growth potential in Enzene Biosciences, Alkem's biotechnology subsidiary
** Sees growth opportunity in co's obesity drug
** Expects Enzene revenue to rise to 8 bln rupees ($91.5 mln) by FY28 vs year-ago 3.6 bln rupees
** Stock rated "hold" on avg; median PT is 5,430 rupees, per data compiled by LSEG
** YTD, ALKE falls 3.2%
($1 = 87.4300 Indian rupees)
(Reporting by Rudra Singh)
(([email protected];))
Aug 12 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM LABORATORIES LTD - TO INCORPORATE SUBSIDIARY IN SAUDI ARABIA
Further company coverage: ALKE.NS
(([email protected];))
Aug 12 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM LABORATORIES LTD - TO INCORPORATE SUBSIDIARY IN SAUDI ARABIA
Further company coverage: ALKE.NS
(([email protected];))
BENGALURU, May 29 (Reuters) - Diary of India economic, corporate events on May 29
ECONOMIC, CORPORATE .BSE500 EVENTS:
Key Speaker | Local Time | Location |
India Chief Economic Advisor, India Trade Minister, India Trade Secretary, India Industry Secretary | 1230-1830 | New Delhi |
Start Date | Start Time | RIC | Company Name | Event Name |
29-May-2025 | NTS | ALKE.NS | Alkem Laboratories Ltd | Q4 2025 Alkem Laboratories Ltd Earnings Release |
29-May-2025 | NTS | AMAR.NS | Amara Raja Energy & Mobility Ltd | Q4 2025 Amara Raja Energy & Mobility Ltd Earnings Release |
29-May-2025 | NTS | BAJA.NS | Bajaj Auto Limited | Q4 2025 Bajaj Auto Limited Earnings Release |
29-May-2025 | NTS | CAMU.NS | Campus Activewear Ltd | Q4 2025 Campus Activewear Ltd Earnings Release |
29-May-2025 | NTS | CNTP.NS | Century Plyboards (India) Ltd | Q4 2025 Century Plyboards (India) Ltd Earnings Release |
29-May-2025 | NTS | ENGI.NS | Engineers India Ltd | Q4 2025 Engineers India Ltd Earnings Release |
29-May-2025 | NTS | GPPL.NS | Gujarat Pipavav Port Ltd | Q4 2025 Gujarat Pipavav Port Ltd Earnings Release |
29-May-2025 | NTS | IPCA.NS | IPCA Laboratories Ltd | Q4 2025 IPCA Laboratories Ltd Earnings Release |
29-May-2025 | NTS | KNRL.NS | KNR Constructions Ltd | Q4 2025 KNR Constructions Ltd Earnings Release |
29-May-2025 | NTS | LEMO.NS | Lemon Tree Hotels Ltd | Q4 2025 Lemon Tree Hotels Ltd Earnings Release |
29-May-2025 | NTS | NBCC.NS | NBCC (India) Ltd | Q4 2025 NBCC (India) Ltd Earnings Release |
29-May-2025 | NTS | PREG.NS | Prestige Estates Projects Ltd | Q4 2025 Prestige Estates Projects Ltd Earnings Release |
29-May-2025 | NTS | PROR.NS | Procter & Gamble Health Ltd | Q3 2025 Procter & Gamble Health Ltd Earnings Release |
29-May-2025 | NTS | SJVN.NS | SJVN Ltd | Q4 2025 SJVN Ltd Earnings Release |
29-May-2025 | NTS | SOBH.NS | Sobha Ltd | Q4 2025 Sobha Ltd Earnings Release |
29-May-2025 | NTS | SUZL.NS | Suzlon Energy Ltd | Q4 2025 Suzlon Energy Ltd Earnings Release |
29-May-2025 | NTS | VARE.NS | Varroc Engineering Ltd | Q4 2025 Varroc Engineering Ltd Earnings Release |
29-May-2025 | NTS | WLSP.NS | Welspun Living Ltd | Q4 2025 Welspun Living Ltd Earnings Release |
NTS - 'No time scheduled'
(Compiled by Bengaluru Newsroom)
BENGALURU, May 29 (Reuters) - Diary of India economic, corporate events on May 29
ECONOMIC, CORPORATE .BSE500 EVENTS:
Key Speaker | Local Time | Location |
India Chief Economic Advisor, India Trade Minister, India Trade Secretary, India Industry Secretary | 1230-1830 | New Delhi |
Start Date | Start Time | RIC | Company Name | Event Name |
29-May-2025 | NTS | ALKE.NS | Alkem Laboratories Ltd | Q4 2025 Alkem Laboratories Ltd Earnings Release |
29-May-2025 | NTS | AMAR.NS | Amara Raja Energy & Mobility Ltd | Q4 2025 Amara Raja Energy & Mobility Ltd Earnings Release |
29-May-2025 | NTS | BAJA.NS | Bajaj Auto Limited | Q4 2025 Bajaj Auto Limited Earnings Release |
29-May-2025 | NTS | CAMU.NS | Campus Activewear Ltd | Q4 2025 Campus Activewear Ltd Earnings Release |
29-May-2025 | NTS | CNTP.NS | Century Plyboards (India) Ltd | Q4 2025 Century Plyboards (India) Ltd Earnings Release |
29-May-2025 | NTS | ENGI.NS | Engineers India Ltd | Q4 2025 Engineers India Ltd Earnings Release |
29-May-2025 | NTS | GPPL.NS | Gujarat Pipavav Port Ltd | Q4 2025 Gujarat Pipavav Port Ltd Earnings Release |
29-May-2025 | NTS | IPCA.NS | IPCA Laboratories Ltd | Q4 2025 IPCA Laboratories Ltd Earnings Release |
29-May-2025 | NTS | KNRL.NS | KNR Constructions Ltd | Q4 2025 KNR Constructions Ltd Earnings Release |
29-May-2025 | NTS | LEMO.NS | Lemon Tree Hotels Ltd | Q4 2025 Lemon Tree Hotels Ltd Earnings Release |
29-May-2025 | NTS | NBCC.NS | NBCC (India) Ltd | Q4 2025 NBCC (India) Ltd Earnings Release |
29-May-2025 | NTS | PREG.NS | Prestige Estates Projects Ltd | Q4 2025 Prestige Estates Projects Ltd Earnings Release |
29-May-2025 | NTS | PROR.NS | Procter & Gamble Health Ltd | Q3 2025 Procter & Gamble Health Ltd Earnings Release |
29-May-2025 | NTS | SJVN.NS | SJVN Ltd | Q4 2025 SJVN Ltd Earnings Release |
29-May-2025 | NTS | SOBH.NS | Sobha Ltd | Q4 2025 Sobha Ltd Earnings Release |
29-May-2025 | NTS | SUZL.NS | Suzlon Energy Ltd | Q4 2025 Suzlon Energy Ltd Earnings Release |
29-May-2025 | NTS | VARE.NS | Varroc Engineering Ltd | Q4 2025 Varroc Engineering Ltd Earnings Release |
29-May-2025 | NTS | WLSP.NS | Welspun Living Ltd | Q4 2025 Welspun Living Ltd Earnings Release |
NTS - 'No time scheduled'
(Compiled by Bengaluru Newsroom)
April 23 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM LABORATORIES LTD - ACQUIRES 100% STAKE IN ADROIT BIOMED
Source text: ID:nBSE2FvKDC
Further company coverage: ALKE.NS
(([email protected];;))
April 23 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM LABORATORIES LTD - ACQUIRES 100% STAKE IN ADROIT BIOMED
Source text: ID:nBSE2FvKDC
Further company coverage: ALKE.NS
(([email protected];;))
Alkem Laboratories Ltd ALKE.NS:
ALKEM LABORATORIES LTD - RECEIVES GST DEMAND ORDER FOR 13.7 MILLION RUPEES
Source text: ID:nBSE2Pb2ks
Further company coverage: ALKE.NS
Alkem Laboratories Ltd ALKE.NS:
ALKEM LABORATORIES LTD - RECEIVES GST DEMAND ORDER FOR 13.7 MILLION RUPEES
Source text: ID:nBSE2Pb2ks
Further company coverage: ALKE.NS
** Shares of Alkem Labs ALKE.NS down 6.4% to 5,151 rupees
** Stock top percentage loser on the Nifty Pharma index .NIPHARM, which is down 1.8%
** The pharma co posted a 5.2% YoY increase in quarterly net profit and a 1.5% rise in revenue on Friday, but both fell short of analysts' estimates
** Brokerage J.P. Morgan cuts its FY25/26/27 earnings estimates by 4%/3%/8% due to softer revenue trends
** Co maintained FY25 EBITDA margin target at 19%, indicating a weak Q4 ahead - J.P. Morgan
** Brokerage adds, concerns remain due to weak India growth and lackluster U.S. portfolio
** Stock rose 8.3% in 2024 vs a 39% gain in .NIPHARM
(Reporting by Yagnoseni Das in Bengaluru)
(([email protected];))
** Shares of Alkem Labs ALKE.NS down 6.4% to 5,151 rupees
** Stock top percentage loser on the Nifty Pharma index .NIPHARM, which is down 1.8%
** The pharma co posted a 5.2% YoY increase in quarterly net profit and a 1.5% rise in revenue on Friday, but both fell short of analysts' estimates
** Brokerage J.P. Morgan cuts its FY25/26/27 earnings estimates by 4%/3%/8% due to softer revenue trends
** Co maintained FY25 EBITDA margin target at 19%, indicating a weak Q4 ahead - J.P. Morgan
** Brokerage adds, concerns remain due to weak India growth and lackluster U.S. portfolio
** Stock rose 8.3% in 2024 vs a 39% gain in .NIPHARM
(Reporting by Yagnoseni Das in Bengaluru)
(([email protected];))
Feb 7 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM MEDTECH TO ACQUIRE 100% STAKE IN BOMBAY ORTHO INDUSTRIES
Source text: ID:nBSEhXggz
Further company coverage: ALKE.NS
(([email protected];;))
Feb 7 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM MEDTECH TO ACQUIRE 100% STAKE IN BOMBAY ORTHO INDUSTRIES
Source text: ID:nBSEhXggz
Further company coverage: ALKE.NS
(([email protected];;))
Feb 4 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM LABS - LAUNCHES KOJIGLO SERUM IN INDIA TO MANAGE FACIAL HYPERPIGMENTATION
Source text: ID:nBSE6t76MZ
Further company coverage: ALKE.NS
(([email protected];;))
Feb 4 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM LABS - LAUNCHES KOJIGLO SERUM IN INDIA TO MANAGE FACIAL HYPERPIGMENTATION
Source text: ID:nBSE6t76MZ
Further company coverage: ALKE.NS
(([email protected];;))
Jan 7 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM LABORATORIES LTD - GETS GST ORDER OF 52.2 MILLION RUPEES, PENALTY OF 52.2 MILLION RUPEES
Source text: [ID:]
Further company coverage: ALKE.NS
(([email protected];))
Jan 7 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM LABORATORIES LTD - GETS GST ORDER OF 52.2 MILLION RUPEES, PENALTY OF 52.2 MILLION RUPEES
Source text: [ID:]
Further company coverage: ALKE.NS
(([email protected];))
Dec 25 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
IT AUTHORITY DISALLOWS TAX DEDUCTION
DISPUTED AMOUNT IS 3.75 BILLION RUPEES
NO MATERIAL IMPACT ON COMPANY AS NO AMOUNT IS PAYABLE
Source text: ID:nBSE8Pxk02
Further company coverage: ALKE.NS
(([email protected];))
Dec 25 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
IT AUTHORITY DISALLOWS TAX DEDUCTION
DISPUTED AMOUNT IS 3.75 BILLION RUPEES
NO MATERIAL IMPACT ON COMPANY AS NO AMOUNT IS PAYABLE
Source text: ID:nBSE8Pxk02
Further company coverage: ALKE.NS
(([email protected];))
More Mid Cap Ideas
See similar 'Mid' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Alkem Laboratories do?
Alkem Laboratories Limited is a prominent Indian pharmaceutical company that develops, manufactures, and markets high-quality pharmaceutical products globally. It excels in acute and chronic therapeutic segments, supported by strong distribution networks and brand building.
Who are the competitors of Alkem Laboratories?
Alkem Laboratories major competitors are Glenmark Pharma., Abbott India, Aurobindo Pharma, Ipca Laboratories, Ajanta Pharma, Glaxosmithkline Phar, Gland Pharma. Market Cap of Alkem Laboratories is ₹66,656 Crs. While the median market cap of its peers are ₹46,277 Crs.
Is Alkem Laboratories financially stable compared to its competitors?
Alkem Laboratories seems to be less financially stable compared to its competitors. Altman Z score of Alkem Laboratories is 8.05 and is ranked 6 out of its 8 competitors.
Does Alkem Laboratories pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Alkem Laboratories latest dividend payout ratio is 24.84% and 3yr average dividend payout ratio is 37.4%
How has Alkem Laboratories allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Alkem Laboratories balance sheet?
Balance sheet of Alkem Laboratories is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Alkem Laboratories improving?
Yes, profit is increasing. The profit of Alkem Laboratories is ₹2,353 Crs for TTM, ₹2,165 Crs for Mar 2025 and ₹1,796 Crs for Mar 2024.
Is the debt of Alkem Laboratories increasing or decreasing?
Yes, The net debt of Alkem Laboratories is increasing. Latest net debt of Alkem Laboratories is -₹109.4 Crs as of Mar-26. This is greater than Mar-25 when it was -₹1,993.61 Crs.
Is Alkem Laboratories stock expensive?
Alkem Laboratories is not expensive. Latest PE of Alkem Laboratories is 28.96, while 3 year average PE is 31.85. Also latest EV/EBITDA of Alkem Laboratories is 22.14 while 3yr average is 24.32.
Has the share price of Alkem Laboratories grown faster than its competition?
Alkem Laboratories has given better returns compared to its competitors. Alkem Laboratories has grown at ~10.83% over the last 5yrs while peers have grown at a median rate of 10.08%
Is the promoter bullish about Alkem Laboratories?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Alkem Laboratories is 49.7% and last quarter promoter holding is 51.2%
Are mutual funds buying/selling Alkem Laboratories?
The mutual fund holding of Alkem Laboratories is increasing. The current mutual fund holding in Alkem Laboratories is 16.71% while previous quarter holding is 15.57%.